Pharming Group NV

Pharming Group NV's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Pharming Group NV has 707.78M shares outstanding.

As of June 30, 2026, Pharming Group NV maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.89, indicating elevated leverage, while an interest coverage ratio of 2.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharming Group NV posted a return on equity (ROE) of 3.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.03, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.76, useful for judging operating efficiency across full business cycles. The company generates approximately 2.14M in revenue per employee across its workforce of 150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.76 indicates how many times Pharming Group NV sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharming Group NV recorded 5.75M in income tax expense. That works out to an effective tax rate of 41.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.87M, leaving 8.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Pharming Group NV generated 320.75M in revenue and converted that into 8.12M in net income, yielding earnings per share of 0.01. EBITDA reached 26.71M, while operating income came in at 10.81M.

As of June 30, 2026, Pharming Group NV holds 138.54M in cash and equivalents against 99.17M in total debt, resulting in a net debt position of -52.88M. Total book value stands at 236.76M, with working capital of 164.07M providing operational flexibility.

Pharming Group NV produced 30.66M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 30.66M - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Pharming Group NV posted a gross margin of 86.53, reflecting its pricing power and cost economics. The operating margin of 3.37 and net profit margin of 2.53 provide insight into operational efficiency.

Pharming Group NV's most recent stock split took place on November 23, 2016.